BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests ...

Chief Operating Officer Ryan Fukushima recently sold a significant portion of his holdings in the company, according to a ...

The Foundation Medicine next-generation sequencing-based panels use Fulgent's technology platform and will analyze genes associated with hereditary cancers.

Erik Phelps, the Executive Vice President and Chief Administrative and Legal Officer of Tempus AI , Inc. (NASDAQ:TEM), ...

The genetic testing results also inform patients’ family members about their cancer risks so they can be proactive in screening and prevention. For now, GENETECA™ is only available to people with ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

Articles were selected for inclusion if they reported on patients with metastatic prostate cancer who received a germline or somatic genomic test and/or made comparisons between those tests, reported ...

Even though a large proportion of cancer patients carry genetic mutations that make them more susceptible to cancer, only a small percentage of them — and their family members — undergo ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...